Trichotillomania Clinical Trial
Official title:
Silymarin Treatment of Trichotillomania in Children and Adults: A Double-Blind, Placebo-Controlled, Cross-Over Study
The goal of the proposed study is to evaluate the efficacy and safety of silymarin (milk thistle) in children and adults with trichotillomania. The hypothesis to be tested is that silymarin will be more effective and well tolerated in children and adults with trichotillomania compared to placebo. The proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.
Pathological hair-pulling, trichotillomania, has been defined as repetitive, intentionally performed pulling that causes noticeable hair loss and results in clinically significant distress or functional impairment. Trichotillomania appears relatively common with an estimated prevalence between 1-3%. Data on the pharmacological treatment of trichotillomania is limited to case reports and conflicting double-blind studies of serotonin reuptake inhibitors. One positive double-blind study of N-acetyl cysteine in adults was not successful when examined for children and adolescents. Available data on the treatment of trichotillomania in children are therefore limited. Silymarin, a flavonoid and a member of the Asteraceae family, is extracted from the seeds of milk thistle (Silybum marianum) and is known to have antioxidative and anti-apoptotic properties. Furthermore, it has been demonstrated that its anti-oxidative activity is related to the scavenging of free radicals and activation of anti-oxidative defenses: increases in cellular glutathione content and superoxide dismutase activity. Milk thistle has been used for a range of psychiatric disorders including methamphetamine abuse and obsessive compulsive disorder. The flavonoid complex silymarin in preclinical studies has been found to increase serotonin and dopamine levels in the cortex. In the frontal cortex one of the functions of dopamine is to increase the signal to noise ratio, increased dopamine correlating with increased frontal performance. Studies have shown that the higher cortical dopamine levels are associated with improved frontal cortical cognitive performance. Cortical inhibition is felt to be the basis for top-down control of motivated behaviors. A recent randomized controlled study with milk thistle was conducted in Iran Thirty five participants with moderate OCD were randomly assigned to 200 mg of milk thistle leaf extract or 10 mg of fluoxetine three times daily for eight weeks. Results revealed no significant difference in treatment effects between milk thistle and fluoxetine from baseline to endpoint as both interventions provided a highly significant reduction in symptoms. Silymarin or Milk Thistle may therefore offer promise for the treatment of individuals with trichotillomania. The current pilot study examines the tolerability and efficacy of milk thistle in the treatment of trichotillomania in children and adults. The investigators hypothesize that milk thistle will reduce the severity of symptoms related to trichotillomania and improve patients' overall functioning. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01445444 -
Habit Reversal Training for Children and Adolescents With Trichotillomania
|
N/A | |
Completed |
NCT04559750 -
Internet CBT for Trichotillomania and Skin Picking Disorder
|
N/A | |
Completed |
NCT01638975 -
Response Inhibition Training for Individuals With Trichotillomania
|
N/A | |
Completed |
NCT00993265 -
N-Acetylcysteine for Pediatric Trichotillomania
|
Phase 2 | |
Completed |
NCT00917098 -
Examining Behavior Therapy for Trichotillomania in Children and Adolescents
|
N/A | |
Recruiting |
NCT00552266 -
Methylphenidate in ADHD With Trichotillomania
|
Phase 4 | |
Completed |
NCT03530800 -
Dronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors
|
Phase 2/Phase 3 | |
Completed |
NCT01984333 -
Online Response Inhibition Training for Trichotillomania
|
N/A | |
Completed |
NCT00740909 -
Cognitive Behavioral Therapy for Trichotillomania
|
Phase 1/Phase 2 | |
Recruiting |
NCT05003401 -
Leveraging Technological Advancements to Improve the Treatment of Trichotillomania
|
N/A | |
Completed |
NCT01875445 -
Inositol in Trichotillomania
|
Phase 2 | |
Completed |
NCT03486041 -
Comprehensive Behavioral (ComB) Model of Treatment for Trichotillomania
|
N/A | |
Completed |
NCT00872742 -
Testing a New Therapy for Trichotillomania
|
Phase 2 | |
Completed |
NCT00182507 -
Olanzapine in the Treatment of Hair Pulling (Trichotillomania)
|
Phase 4 | |
Completed |
NCT00947154 -
Trial of Aripiprazole in Trichotillomania
|
N/A | |
Completed |
NCT00354770 -
N-Acetyl Cysteine in Trichotillomania
|
Phase 2 | |
Completed |
NCT00004550 -
Evaluation and Follow-up of Individuals With Obsessive-Compulsive Disorder and Related Conditions
|
N/A | |
Completed |
NCT01878110 -
Efficacy of COMB (Comprehensive Behavioral) Model of Treatment of Trichotillomania
|
N/A | |
Active, not recruiting |
NCT01075672 -
Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals
|
N/A | |
Completed |
NCT01968343 -
Trichotillomania: Group Cognitive-Behavioral Therapy
|
Phase 2 |